Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Century Therapeutics Inc (NQ: IPSC )

3.170 +0.170 (+5.67%)
Streaming Delayed Price Updated: 9:49 AM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Century Therapeutics Inc

< Previous 1 2 Next >
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational... 
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Leadership Changes
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the AACR Annual Meeting 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.